A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas

Figure 3

The risk classification of the pseudogene methylation signature in molecularly and clinically stratified cohorts. Risk classification and forest plots of comparison in OS for low-risk vs. high-risk patients from a combined cohort (TCGA, GSE60274, and RAUH collectively) who have (a) an MGMT methylated tumor, (b) an MGMT unmethylated tumor, (c) an age<60 years old or (d) an age ≥60 years old; and AUC comparison in (e) all available patients with RT/TMZ or in (f) all available RT/TMZ-treated patients with different ages.

(a)

(b)

(c)

(d)

(e)

(f)